Dose Course 2018_Flipping book

46

Taking patient specific QA further…

❑ “none of the approaches tested to verify IMRT plans by means of gamma analysis using 3%/3 mm or 2%/2 mm criteria solve the problem of evaluating treatment plans. Neither is it clear whether global 3D gamma analysis is superior to local 3D gamma analysis. ” - Carrasco et al 2012 ❑ “a suitable alternative for evaluating and reporting the measured planar differences is to transfer their impact to the plan DVH and then to compare the resulting DVHs with the clinical tolerances of the PTV and OAR. ” - Carrasco et al 2012 ❑ “the essence of patient-specific IMRT QA is to ensure that the dose distribution that is going to be delivered to the patient is of the same comparable quality as the approved plan , and such quality is evaluated by patient dose statistics and DVH curves.” - Zhen – et al 2011 ❑ “ The evolution from gamma passing rates to DVH based metrics is natural in this way. ” – Zhen –et al 2011

Dublin 2018